Obeticholic acid for the treatment of NASH

Hindson, Jordan

doi:10.1038/s41575-020-0264-1

Cited by 12 publications

(11 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another systemic review recommended UDCA as a frontline therapeutic option for NASH, thereby preventing its progression to cirrhosis and liver cancer [119]. Obeticholic acid: This synthetic farnesoid X receptor agonist at a dose of 25 mg daily is associated with histological improvement of NASH [120,121]. Obeticholic acid might become the first approved pharmacotherapy for NASH fibrosis after result of recent multicentre, randomized, placebo-controlled phase 3 trial done by Younossi et al [122].…”

Section: Emerging Genetic Biomarkers For Diagnosis Of Different Stagementioning

confidence: 99%

Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult

Paul

2020

Egypt Liver Journal

View full text Add to dashboard Cite

Background: Number of non-alcoholic fatty liver disease (NAFLD) cases is increasing over time due to alteration of food habit, increase incidence of metabolic syndrome, and lack of exercise. Liver biopsy is the test for diagnosis and staging of NAFLD, but nowadays several biochemical markers, scoring systems, and imaging studies are available to diagnose and stage NAFLD which is linked to end-stage liver disease, hepatocellular cancer, and elevated cardiovascular-and cancer-related morbidity and mortality. Therefore urgent diagnosis and management are required to avoid complications related to NAFLD. This review summarizes recent advances in diagnosis and medical management of non-alcoholic fatty liver disease. Main text: Recently published studies from PubMed, Red Cross, Copernicus, and also various previous studies were reviewed. We have discussed various non-invasive methods for detection of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis (NASH), and hepatic fibrosis. Non pharmacological therapies for NAFLD, indications, and approved medications for NAFLD and other commonly used non-approved medications have been discussed in this review article. Conclusions: Multiple non-invasive tests are available for diagnosis of NAFLD, and its different stages however gold standard test is liver biopsy. NALFD without NASH and significant fibrosis is treated by lifestyle modifications which include moderate to vigorous exercise and diet modification. To improve hepatic steatosis, minimum of 3-5% of body weight loss is necessary, but > 7-10% weight reductions is required for histological improvement in NASH and fibrosis. Pharmacotherapy is indicated when patient is having NASH with significant fibrosis.

show abstract

Section: Emerging Genetic Biomarkers For Diagnosis Of Different Stagementioning

confidence: 99%

Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult

Paul

2020

Egypt Liver Journal

View full text Add to dashboard Cite

show abstract

“…OCA leads to weight loss in patients with NASH, and weight loss caused by OCA is shown to exert additively beneficial effects on serum aminotransferase and liver histology [134]. Additionally, it significantly improves fibrosis in NASH patients [135]. It is one of the most promising drugs for treating NASH and is now in phase 3 clinical trials [136].…”

Section: Pioglitazonementioning

confidence: 99%

Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC

Kim

Lee

et al. 2021

IJMS

View full text Add to dashboard Cite

Liver disease is the spectrum of liver damage ranging from simple steatosis called as nonalcoholic fatty liver disease (NAFLD) to hepatocellular carcinoma (HCC). Clinically, NAFLD and type 2 diabetes coexist. Type 2 diabetes contributes to biological processes driving the severity of NAFLD, the primary cause for development of chronic liver diseases. In the last 20 years, the rate of non-viral NAFLD/NASH-derived HCC has been increasing rapidly. As there are currently no suitable drugs for treatment of NAFLD and NASH, a class of thiazolidinediones (TZDs) drugs for the treatment of type 2 diabetes is sometimes used to improve liver failure despite the risk of side effects. Therefore, diagnosis, prevention, and treatment of the development and progression of NAFLD and NASH are important issues. In this review, we will discuss the pathogenesis of NAFLD/NASH and NAFLD/NASH-derived HCC and the current promising pharmacological therapies of NAFLD/NASH. Further, we will provide insights into “adipose-derived adipokines” and “liver-derived hepatokines” as diagnostic and therapeutic targets from NAFLD to HCC.

show abstract

“…From a clinical point of view, administration of OCA in a phase II trial in NAFLD and T2DM patients resulted in an amelioration of insulin sensitivity and a decrease in liver proinflammatory markers [ 172 ]. Moreover, in a phase III clinical trial for treating NASH, the administration of 25 mg of OCA on a daily basis during 18 months improved fibrosis in NASH patients [ 173 ]. Noteworthy, some safety concerns have been raised regarding this compound such as an increased level of serum LDL cholesterol, decreased level of serum HDL cholesterol, gastrointestinal issues and pruritus.…”

Section: Therapeutic Strategiesmentioning

confidence: 99%

The Liver under the Spotlight: Bile Acids and Oxysterols as Pivotal Actors Controlling Metabolism

Lefort

Cani

2021

Cells

View full text Add to dashboard Cite

Among the myriad of molecules produced by the liver, both bile acids and their precursors, the oxysterols are becoming pivotal bioactive lipids which have been underestimated for a long time. Their actions are ranging from regulation of energy homeostasis (i.e., glucose and lipid metabolism) to inflammation and immunity, thereby opening the avenue to new treatments to tackle metabolic disorders associated with obesity (e.g., type 2 diabetes and hepatic steatosis) and inflammatory diseases. Here, we review the biosynthesis of these endocrine factors including their interconnection with the gut microbiota and their impact on host homeostasis as well as their attractive potential for the development of therapeutic strategies for metabolic disorders.

show abstract

Obeticholic acid for the treatment of NASH

Cited by 12 publications

References 1 publication

Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult

Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult

Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC

The Liver under the Spotlight: Bile Acids and Oxysterols as Pivotal Actors Controlling Metabolism

Contact Info

Product

Resources

About